Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells

Research output: Contribution to journalArticlepeer-review

93 Scopus citations


Stem cells harvested from peripheral blood are the most commonly used graft source in hematopoietic stem cell transplantation. While G-CSF is the most frequently used agent for stem cell mobilization, the use of G-CSF alone results in suboptimal stem cell yields in a significant proportion of patients undergoing autologous transplantation. Plerixafor (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor CR4. Plerixafor results in the rapid and reversible mobilization of hematopoietic stem cells into the peripheral circulation and is synergistic when combined with G-CSF. In clinical studies of autologous stem cell transplantation, the combination of plerixafor and G-CSF allows the collection of large numbers of stem cells in fewer apheresis sessions and can salvage those who fail G-CSF mobilization alone.

Original languageEnglish
Pages (from-to)1797-1804
Number of pages8
JournalExpert opinion on biological therapy
Issue number11
StatePublished - Nov 2008


  • AMD3100
  • CXCL12
  • CXCR4
  • Hematopoietic stem cell transplantation
  • SDF-1
  • Stem cell mobilization


Dive into the research topics of 'Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells'. Together they form a unique fingerprint.

Cite this